Viruses 2011, 3(5), 469-483; doi:10.3390/v3050469
Article

Susceptibility of Primary HTLV-1 Isolates from Patients with HTLV-1-Associated Myelopathy to Reverse Transcriptase Inhibitors

1,5email, 1email, 1email, 2email, 3email, 4,6email and 2,3,* email
Received: 25 February 2011; in revised form: 6 April 2011 / Accepted: 21 April 2011 / Published: 5 May 2011
(This article belongs to the Special Issue Recent Developments in HTLV Research)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Since human T-lymphotropic virus type 1 (HTLV-1)-associated diseases are associated with a high HTLV-1 load, reducing this load may treat or prevent disease. However, despite in vitro evidence that certain nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs) are active against HTLV-1, in vivo results have been disappointing. We therefore assayed the sensitivity of HTLV-1 primary isolates to a panel of RT inhibitors. HTLV-1 primary isolates were obtained, pre- and post- NRTI treatment, from patients with HTLV-1-associated myelopathy. Sensitivity to azidothymidine (AZT), lamivudine (3TC), tenofovir (TDF) and three phosphonated carbocyclic 2’-oxa-3’aza nucleosides (PCOANs) was assessed in a RT inhibitor assay. With the exception of 3TC, HTLV RT from primary isolates was less sensitive to all tested inhibitors than HTLV-1 RT from MT-2 cells. HTLV-1 RT from primary isolates and from chronically infected, transformed MT-2 cells was insensitive to 3TC. Sensitivity of primary isolates to RT inhibitors was not reduced following up to 12 months of patient treatment with AZT plus 3TC. The sensitivity of HTLV-1 primary isolates to NRTIs differs from that of cell lines and may vary among patients. Failure of NRTIs to reduce HTLV-1 viral load in vivo was not due to the development of phenotypic NRTI resistance. AZT and the three PCOANs assayed all consistently inhibited primary isolate HTLV-1 RT.
Keywords: Human T-cell Lymphotropic Virus type 1; primary isolates; reverse transcriptase; drug sensitivity; azidothymidine; lamivudine; tenofovir; phosphonated carbocyclic 2’-oxa-3’aza nucleosides
PDF Full-text Download PDF Full-Text [308 KB, Updated Version, uploaded 6 May 2011 11:51 CEST]
The original version is still available [360 KB, uploaded 5 May 2011 16:52 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Macchi, B.; Balestrieri, E.; Ascolani, A.; Hilburn, S.; Martin, F.; Mastino, A.; Taylor, G.P. Susceptibility of Primary HTLV-1 Isolates from Patients with HTLV-1-Associated Myelopathy to Reverse Transcriptase Inhibitors. Viruses 2011, 3, 469-483.

AMA Style

Macchi B, Balestrieri E, Ascolani A, Hilburn S, Martin F, Mastino A, Taylor GP. Susceptibility of Primary HTLV-1 Isolates from Patients with HTLV-1-Associated Myelopathy to Reverse Transcriptase Inhibitors. Viruses. 2011; 3(5):469-483.

Chicago/Turabian Style

Macchi, Beatrice; Balestrieri, Emanuela; Ascolani, Arianna; Hilburn, Silva; Martin, Fabiola; Mastino, Antonio; Taylor, Graham P. 2011. "Susceptibility of Primary HTLV-1 Isolates from Patients with HTLV-1-Associated Myelopathy to Reverse Transcriptase Inhibitors." Viruses 3, no. 5: 469-483.


Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert